The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Xiuying Hu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou, China; School of Basic Medical Sciences, Guizhou Medical Univer…. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Leukemia, Myeloid, Acute, Aldehyde Dehydrogenase, Mitochondrial, Protein Kinase C-delta. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guizhou Medical University, Health Commission of Guizhou Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Leukemia stem cells (LSCs) exhibit unique characteristics distinct from those of leukemia cells and are insensitive to conventional chemotherapeutics; thus, these cells ultimately contribute to treatment failure and relapse in acute myeloid leukemia (AML) patients. A critical challenge remains as strategies are needed to precisely target the diverse molecular drivers of leukemia stem cells (LSCs), particularly in the context of their protective microenvironment, to achieve optimal therapeutic outcomes. In this study, we investigated the role of aldehyde dehydrogenase 2 (ALDH2) in chemotherapy resistance in patients with relapsed/refractory AML and demonstrated that elevated ALDH2 expression in LSCs is closely associated with AML relapse and treatment resistance. Mechanistically, ALDH2 sustains mitochondrial homeostasis in LSCs by increasing the expression of protein kinase C delta (PKC delta) and serine hydroxymethyltransferase 2 (SHMT2), revealing a previously unidentified mechanism of metabolic reprogramming that facilitates LSC adaptation to chemotherapy-induced stress. The ALDH2‒PKC delta-SHMT2 axis plays a pivotal role in conferring resistance to chemotherapy in LSCs. Notably, rhoifolin, a compound designed to inhibit the specific binding site of ALDH2-PKC delta, significantly increased chemosensitivity. It could target LSCs within the bone marrow microenvironment, work synergistically with conventional chemotherapy drugs, and exhibit no toxicity toward normal cells. These findings underscore the therapeutic potential of targeting the ALDH2‒PKC delta axis as a novel and effective strategy for the treatment of AML and the eradication of minimal residual disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou, China; School of Basic Medical Sciences, Guizhou Medical University, Guizhou, China; Hematological Institute of Guizhou Province, Gui…
- Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou, China; Hematological Institute of Guizhou Province, Guizhou, China; Guizhou Province Hematopoietic Stem Cell Transplantation Centre a…
- Guizhou Province Hematopoietic Stem Cell Transplantation Centre and Key Laboratory of Hematological Disease Diagnostic and Treatment Centre, Guizhou, China.
- School of Basic Medical Sciences, Guizhou Medical University, Guizhou, China; Guizhou Province Hematopoietic Stem Cell Transplantation Centre and Key Laboratory of Hematological Disease Diagnostic and Treatment Centre,…
- Department of Pharmacy, Daqin Cancer Hospital of Guizhou Province, Guiyang, Guizhou, China.
- Department of Pharmacy, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China. Electronic address: fangqin@gmc.edu.cn.
Förderung
- National Natural Science Foundation of China
- Guizhou Medical University
- Health Commission of Guizhou Province
Zitieren
APA
Hu, X., Hu, T., Cao, S., Zheng, L., Ni, M., Shang, Q., Li, Y., Luo, H., Zhao, N., Wang, L., Zhang, Y., Zhao, J., Cheng, B., Pan, C., Zhang, T., Jiang, L., Kang, Q., Fang, Q., & Wang, J. (2025). The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217963
Vancouver
Hu X, Hu T, Cao S, Zheng L, Ni M, Shang Q, et al. The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217963
BibTeX
@article{Hu2025,
author = {Hu, Xiuying and Hu, Tianzhen and Cao, Shuyun and Zheng, Lin and Ni, Ming and Shang, Qin and Li, Yanju and Luo, Hong and Zhao, Naiqin and Wang, Li and Zhang, Yaming and Zhao, Jiangyuan and Cheng, Bingqing and Pan, Chengyun and Zhang, Tianzhuo and Jiang, Li and Kang, Qian and Fang, Qin and Wang, Jishi},
title = {The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217963}
}
EUVIMED